Fig. 3From: Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort studyCumulative incidence of study outcomes for nirmatrelvir-ritonavir recipients vs azvudine recipients, further stratified by duration from symptom onset to treatment initiationBack to article page